Table 4.

OR for rapid renal function decline conferred to the A-FABP levels

Variable	All		Male		Female
	ORa (95% CI)	P value	ORa (95% CI)	P value	ORa (95% CI)	P value
Model 1	1.81 (1.17–2.80)	0.002	1.68 (0.97–2.91)	0.063	3.27 (1.31–8.15)	0.011
Model 2	3.04 (1.53–6.06)	0.002	2.51 (1.08–5.86)	0.033	5.63 (1.33–23.88)	0.019
Model 3	3.10 (1.53–6.29)	0.002	2.65 (1.10–6.38)	0.030	5.65 (1.17–27.19)	0.031

All models were constructed by the logistic regression analysis. Model 1: adjusted for age. Model 2: model 1+adjustments for sex, duration of diabetes, body mass index, systolic blood pressure, history of cardiovascular disease, baseline estimated glomerular filtration rate, log urine albumin creatinine ratio, total cholesterol, glycosylated hemoglobin, and log high-sensitivity C-reactive protein. Model 3: model 2+adjustment for use of thiazolidinedione, insulin, angiotensin-converting-enzyme inhibitor/angiotensin II-receptor blocker and statin.

OR, odds ratio; A-FABP, adipocyte fatty acid-binding protein; CI, confidence interval.

^aValues are presented adjusted OR of log-transformed A-FABP.